Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Packaging materials can be a potential source of nitrosamines, either through the migration of these compounds from the packaging into the drug product or through chemical reactions that occur within the packaging environment.
Balancing risk assessment and confirmatory testing for nitrosamines is a complex task that requires a deep understanding of both the product and the processes involved in its manufacture. By creating a thorough risk assessment, gathering sufficient scientific data, ensuring analytical
By conducting thorough inventory assessments, reviewing manufacturing processes, and understanding the regulatory landscape, companies can proactively manage nitrosamine risks. Regular testing, compliance with global guidelines, and a focus on cross-departmental communication are essential steps in mitigating the risks associated with
Calculating acceptable intake (AI) limits for nitrosamines in pharmaceuticals is critical to ensuring patient safety. By accurately determining AI limits, we can minimize potential carcinogenic risks and maintain the highest standards of drug safety.
ICH Guideline M7 provides a solid framework for the management of nitrosamines in medicinal products. By following these guidelines and implementing a comprehensive lifecycle management approach, pharmaceutical companies can effectively minimize the risks associated with nitrosamine impurities. This ensures the
The Nitrosamine Risk Assessment Questionnaire for APIs is an indispensable tool for pharmaceutical manufacturers. It provides a structured approach to identifying potential sources of nitrosamine contamination and implementing effective mitigation strategies.
Understanding the conditions that lead to nitrosamine formation is crucial for reducing their presence in our food. This article explores the science behind nitrosamine formation in cured meats and offers practical tips for minimizing their levels, ensuring a safer and
Navigating NDSRI regulatory reporting requirements is crucial for pharmaceutical companies to ensure compliance and patient safety. These regulations mandate timely and accurate reporting of nitrosamine impurities in medicines. Understanding the timeline for these requirements helps streamline processes and avoid costly
Implementing effective strategies involves six crucial steps: conducting thorough risk assessments, optimizing manufacturing processes, using high-purity raw materials, performing rigorous analytical testing, adhering to regulatory guidelines, and maintaining continuous monitoring and quality control. These measures collectively minimize nitrosamine risks in
In the pharmaceutical industry, nitrosamines pose significant health risks due to their carcinogenic potential. This blog explores how big data analytics revolutionizes nitrosamine risk assessment by enabling accurate monitoring and prediction. By leveraging vast datasets and predictive models, companies can